



Published in final edited form as:

J Clin Psychiatry. 2009 December ; 70(12): 1662. doi:10.4088/JCP.08m04659.

Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to an *N*-Methyl-D-Aspartate Antagonist

Rodrigo Machado-Vieira, MD, PhD, Peixiong Yuan, MD, PhD, Nancy Brutsche, MSN, Nancy DiazGranados, MD, David Luckenbaugh, MA, Husseini K. Manji, MD, FRCPC, and Carlos A. Zarate Jr, MD

Mood and Anxiety Disorders Program (all authors) and the Laboratory of Molecular Psychiatry and Experimental Therapeutics (Drs Machado-Vieira, Yuan, DiazGranados, Manji, and Zarate), National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, Maryland

Abstract

Objective—A model has been proposed to explain the pathophysiology of mood disorders based on decreased neurotrophin levels during mood episodes; treatment with antidepressants and mood stabilizers is associated with clinical improvement. This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of ketamine, a high-affinity *N*-methyl-D-aspartate (NMDA) antagonist.

Method—Twenty-three subjects aged 18 to 65 years with *DSM-IV* major depressive disorder (treatment resistant) participated in this study, which was conducted between October 2006 and May 2008. The subjects were given an open-label intravenous infusion of ketamine hydrochloride (0.5 mg/kg) and rated using various depression scales at baseline and at 40, 80, 120, and 230 minutes postinfusion. The primary outcome measure was the Montgomery-Asberg Depression Rating Scale score. BDNF levels were obtained at the same time points as depression rating scale scores.

Results—Despite a significant ($P < .001$) improvement in MADRS scores after subjects received ketamine treatment, no changes in BDNF levels were observed in subjects after they received ketamine compared to baseline. Also, no association was found between antidepressant response and BDNF levels.

Conclusions—This study demonstrates that ketamine's rapid initial antidepressant effects are not mediated by BDNF. Further studies are necessary to shed light on the neurobiological basis of these effects.

Individuals with major depressive disorder (MDD) exhibit diverse brain abnormalities associated with impairment of plasticity cascades, including morphological and functional changes in limbic and cortical areas.^{1,2} Similarly, increasing evidence has implicated neurotrophic factors in the pathophysiology of mood disorders.³ Neurotrophic factors have been shown to play an important role in neuronal plasticity, axonal growth, and connectivity.

3

Corresponding author: Carlos A. Zarate Jr, MD, 10 Center Dr, CRC, Unit 7 Southeast, Room 7-3445, Bethesda, MD 20892 (zaratec@mail.nih.gov).

Trial Registration: clinicaltrials.gov Identifiers: NCT00024635 and NCT00088699

Financial disclosure: Drs Zarate and Manji have a patent pending on the use of ketamine in depression and have assigned their patent rights on ketamine to the US government. Drs Machado-Vieira, Yuan, and DiazGranados and Ms Brutsche and Mr Luckenbaugh have no conflict of interest, financial or otherwise, to disclose.

Drug names: ketamine (Ketalar and others), riluzole (Rilutek and others).

Brain-derived neurotrophic factor (BDNF) is the most studied neurotrophin in the pathophysiology of MDD. Postmortem studies have found that depressed subjects have decreased hippocampal and cortical BDNF levels,^{4,5} and BDNF has been found to be down-regulated by stress, which has been directly implicated in the pathophysiology of depression.⁶ Reinforcing this association, a polymorphism in the BDNF gene has been linked with depression-related traits.⁷ Reductions in peripheral BDNF levels have also been described during major depressive episodes, with reports of rescue effects following treatment with various antidepressants.^{5,8–11} Diverse classes of antidepressants induce differential regulatory effects on BDNF levels and expression in humans and animals during depressive states,^{12–16} with differences observed between acute and chronic treatment. Recently, a meta-analysis showed a significant decrease in BDNF levels in depressed subjects compared to healthy controls.⁷ Similarly, the authors found higher BDNF levels after chronic treatment with antidepressants⁷; however, not all studies have found increased BDNF levels after antidepressant treatment.¹⁷

Neurotrophins are present in blood and cross the blood-brain barrier through a high-capacity, saturable transport system.¹⁸ Specifically, BDNF is expressed in many body tissues at relatively high levels.¹⁹ A strong association has been reported between serum and cortical BDNF levels ($r = 0.81$) in rats,⁵ suggesting a relationship between central and peripheral levels. However, although plasma BDNF appears to reflect its brain levels, little is known about which brain regions are more influential in the correlated peripheral changes.

The possibility of therapeutics with rapid antidepressant effects is a new and promising paradigm in the research and treatment of MDD. Although these effects may involve the activation of plasticity pathways, overall their potential neurobiological basis is still poorly understood.²⁰ Glutamatergic modulating agents, in particular ketamine (a high-affinity *N*-methyl-D-aspartate [NMDA] antagonist), has been shown to induce rapid antidepressant effects both in humans and in preclinical models.^{21,22} In addition, previous studies have shown that ketamine's antidepressant effects in patients with treatment-resistant MDD were not only rapid but also sustained for more than 1 week, well beyond the 2-hour half-life of ketamine.^{21,22} Studies are currently underway to determine the biological underpinnings of ketamine's antidepressant effects. One report found that the acute administration of ketamine induced both antidepressant-like effects and increased hippocampal BDNF levels in rats.²³ Another study suggested that the cellular mechanisms underlying ketamine's antidepressant effects might take place through enhanced glutamatergic throughput of α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors relative to NMDA, which leads to synaptic potentiation.²⁴ These findings are notable in the context of the present investigation. It is now clear that in the mature central nervous system, the major function of BDNF is to regulate "here and now" synaptic plasticity.²⁵ Thus, while one might not expect major neuronal remodeling to occur in the short time frame that ketamine exerts its antidepressant effects, ketamine-induced increases in BDNF levels could have a major effect on synaptic function.

Given the potential role of BDNF in synaptic plasticity, the present study sought to investigate the role of BDNF in ketamine's initial antidepressant effects.

METHOD

Twenty-three patients aged 18 to 65 years old participated in this study between October 2006 and May 2008. Participants fulfilled *DSM-IV* criteria for MDD (treatment resistant) and had no diagnosis of alcohol or substance abuse or dependence in the past 90 days, as determined by the Structured Clinical Interview dependence in the past 90 days, as determined by the Structured Clinical Interview for *DSM-IV*.²⁶ Patients with a *DSM-IV* diagnosis of bipolar

disorder or those who had a history of antidepressant- or substance-induced hypomania or mania were excluded. Inclusion criteria were a Montgomery-Asberg Depression Rating Scale (MADRS)²⁷ score of at least 22, a current or past history of lack of response to 2 adequate antidepressant trials, and a current major depressive episode of at least 4 weeks' duration. All patients were drug free, were in good health, and were unmedicated for at least 2 weeks prior to the ketamine infusion, as determined by medical history, physical examination, routine blood laboratories, electrocardiogram, urinalysis, and urine toxicology. Patients received a complete description of the study, and written informed consent was subsequently obtained. The study was approved by the Combined Neuroscience Institutional Review Board of the National Institutes of Health.

Patients underwent a single, open-label infusion of ketamine hydrochloride (0.5 mg/kg), infused over 40 minutes, followed by a double-blind randomization to riluzole or placebo at 6 hours postinfusion. Here we report only the results of the open-label ketamine phase (up to 230 minutes postinfusion). A previous study found that 88% of all responders to ketamine reached response criteria by 230 minutes.²² Ratings included the MADRS, the 17-item Hamilton Depression Rating Scale (HDRS),²⁸ the Beck Depression Inventory (BDI),²⁹ the Brief Psychiatric Rating Scale (BPRS),³⁰⁻³¹ and the Young Mania Rating Scale (YMRS). 32 Ratings were obtained at baseline (60 minutes prior to the infusion) and at 40, 80, 120, and 230 minutes postinfusion. Blood samples were collected using the vacutainer system at 60 minutes before and at 40, 80, 120, and 230 minutes after a single intravenous infusion of ketamine—the same time points as those used with the depression ratings. Response was defined as a 50% or greater decrease from baseline in MADRS scores.

Blood samples were centrifuged at 1,000 rpm at 4°C for 5 minutes and stored at -80°C until assay. Brain-derived neurotrophic factor was measured using an anti-BDNF sandwich ELISA kit (Chemicon International, Temecula, California) according to the manufacturer's instructions. Plasma was diluted 1:2 with sample buffer and carried out in duplicate blind to clinical information. Brain-derived neurotrophic factor standard solution was diluted to concentrations from 7.8 to 500 pg/mL of BDNF in a microplate reader in order to create the standard curve for BDNF levels. After the addition of streptavidin enzyme, substrate, and stop solution, BDNF levels were determined by absorbance in 450 nm using optical density values based on the standard curve values.

Statistics

A linear mixed model was used to examine changes in BDNF levels and depression rating scale scores over time. Schwarz's Bayesian information criterion was used to determine the best-fitting covariance structure that was first-order autoregressive. Initially, time was the only factor. A fixed intercept was included along with a random effect for subject. An additional analysis of BDNF levels added a fixed effect for antidepressant response versus nonresponse and its interaction with time. Montgomery-Asberg Depression Rating Scale score was the primary measure per protocol, but scores obtained from other psychiatric rating scales were also tested for confirmation. Bonferroni post hoc tests examined the change from baseline at each time point as well as group differences at each time point. Further analysis examined the influence of sex, age, and body mass index (BMI) separately to avoid potential confounds by adding these variables as covariates.

Pearson correlations were used to understand the association between BDNF levels and depression rating scale scores. Correlations were performed with the raw values, changes from baseline, baseline BDNF levels with raw depression rating scale scores, and baseline BDNF levels with changes in depression rating scale scores, and baseline BDNF levels with changes in depression rating scale scores, all at each time point. Significance was evaluated at $P < .05$, 2-tailed.

RESULTS

Table 1 summarizes the demographic and clinical characteristics of subjects participating in the study. The initial examination of BDNF levels over time showed no significant changes ($F_{4,73} = 1.15, P = .34$). This suggests that ketamine infusion did not substantially alter BDNF levels. However, MADRS scores changed significantly ($F_{4,81} = 24.70, P < .001$). Post hoc tests showed significant improvement beginning at the first postinfusion time point and lasting through the final one.

Given the change in depression rating scale scores but lack of change in BDNF levels, a variety of approaches were taken to understand any potential relationship between these 2 measures. First, a linear mixed model compared BDNF levels over time in ketamine responders versus nonresponders. This model showed no significant effect of time ($F_{4,69} = 1.15, P = .34$), response ($F_{4,26} = 0.23, P = .64$), or their interaction ($F_{4,69} = 0.50, P = .74$) (Figure 1). Further models covarying age, sex, and BMI separately showed no statistically significant results.

Next, correlations between BDNF levels and MADRS scores were performed for the raw values at each time point. The only significant correlation was at the 80-minute time point ($r = 0.43, P = .04$), but this did not remain significant after we corrected for multiple comparisons. Furthermore, similar correlations with the HDRS were not statistically significant at any time. Additional correlations between changes in BDNF levels and changes in depression rating scale scores, and baseline BDNF levels and either depression rating scale scores or changes in depression rating scale levels and either depression rating scale scores or changes in depression rating scale scores, did not yield any significant relationships (r 's $< 0.29, P$'s $> .19$).

DISCUSSION

This study sought to determine whether BDNF is involved in ketamine's rapid antidepressant effects. The study found that (1) ketamine induced a significant and rapid antidepressant response, consistent with previous studies^{21,22}; (2) BDNF levels showed no changes from baseline after ketamine infusion and at any time up to 230 minutes postinfusion (a time point when antidepressant effects and response were manifest); and (3) BDNF levels showed no association with the observed antidepressant response.

Studies have shown that antidepressants targeting different systems result in regulatory effects on BDNF.¹²⁻¹⁶ These differential effects may account for the heterogeneous data regarding antidepressant regulation in MDD. Specifically, in contrast to a previous animal study showing increased BDNF levels after treatment with ketamine (15 mg/kg),²³ our data failed to demonstrate that BDNF is involved in ketamine's rapid antidepressant response in subjects with MDD.

Several studies have shown reduced peripheral BDNF levels in subjects with MDD compared to healthy control subjects, supporting the role of BDNF as a state-dependent biomarker (reviewed by Sen and colleagues⁷). Notably, it has been shown that dissimilar classes of antidepressants can differentially regulate BDNF levels.¹⁵ Given the strong body of evidence showing decreased BDNF levels in subjects with MDD versus healthy controls, here we aimed to include only patients presenting with a major depressive episode in a drug-free state, focusing on the potential association between BDNF levels and ketamine's initial antidepressant effects and the potential role of BDNF as a surrogate outcome.

It is important to mention the complex mechanisms underlying BDNF storage/release from blood cells.¹¹ Changes in plasma BDNF occur rapidly. A complete plasma/brain BDNF turnover takes approximately 6 minutes; it appears to be bidirectional and seems to be a good

marker of recent brain BDNF levels.^{18,33,34} Brain BDNF is stable in circulating blood for 60 minutes and crosses the blood-brain barrier intact.¹⁸

Overall, total plasma BDNF levels do not appear to play a major role in ketamine's rapid antidepressant effects. However, ketamine might have particular effects on exon-specific BDNF transcript levels known to share functions with immediate early genes (exons III and IV), thus potentially bringing about faster modifications than those depending on recurrent protein synthesis for their transcription (exons I and II). In other words, different BDNF transcript regulation may account for the rapid (hours) and sustained (days/weeks) antidepressant actions of ketamine. In this study, we evaluated *only* the rapid initial effects, possibly through fast activation of exons associated with the induction of immediate early genes. It does thus remain a possibility that BDNF levels could change at later time points and might be more immediately involved in ketamine's sustained, rather than acute, antidepressant effects.

Our knowledge of the mechanisms involved in the therapeutic actions of ketamine as an antidepressant is incomplete, and further studies in this area are urgently needed. The present results suggest that increased serum BDNF levels might be neither critical nor enough for a rapid initial improvement in major depressive episodes. Indeed, a recent article highlights the importance of considering new models to understand the complex interplay of neurotrophic factors and other systems to better advance our understanding of depressive disorders.¹⁷ Specifically, activation of AMPA receptor plasticity pathways has recently been proposed to play a critical role in ketamine's rapid antidepressant effects.^{24,35} These rapid effects on depressive symptoms (and possibly potentiation of synaptic plasticity) seem to take place through a direct trafficking of AMPA receptors (fast-acting ionic glutamatergic receptors) into the postsynaptic membrane, changing membrane potential without direct regulation by BDNF. We conclude that further studies evaluating the role of BDNF in ketamine's sustained antidepressant effects (days/few weeks) are necessary to provide further insight into this topic.

Acknowledgments

Funding/support: This study was supported by the Intramural Research Program at the NIMH and the National Alliance for Research on Schizophrenia and Depression (Dr. Zarate).

Ioline Henter, MA, Mood and Anxiety Disorders Program, NIMH-NIH, provided outstanding editorial assistance.

References

1. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. *Biol Psychiatry* 2006;59(11):1006–1020.10.1016/j.biopsych.2005.10.021 [PubMed: 16487491]
2. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. *Nature* 1997;386(6627):824–827.10.1038/386824a0 [PubMed: 9126739]
3. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. *Neuromolecular Med* 2004;5(1):11–25.10.1385/NMM:5:1:011 [PubMed: 15001809]
4. Altar CA. Neurotrophins and depression. *Trends Pharmacol Sci* 1999;20(2):59–61.10.1016/S0165-6147(99)01309-7 [PubMed: 10101965]
5. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. *Psychiatry Res* 2002;109(2):143–148.10.1016/S0165-1781(02)00005-7 [PubMed: 11927139]
6. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry* 2006;59(12):1116–1127.10.1016/j.biopsych.2006.02.013 [PubMed: 16631126]

7. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. *Biol Psychiatry* 2008;64:527–532.10.1016/j.biopsych.2008.05.005 [PubMed: 18571629]
8. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. *Biol Psychiatry* 2003;54(1):70–75.10.1016/S0006-3223(03)00181-1 [PubMed: 12842310]
9. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. *Prog Neuropsychopharmacol Biol Psychiatry* 2005;29(2):261–265.10.1016/j.pnpbp.2004.11.009 [PubMed: 15694233]
10. Gervasoni N, Aubry JM, Bondolfi G, et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. *Neuropsychobiology* 2005;51(4):234–238.10.1159/000085725 [PubMed: 15897674]
11. Karege F, Bondolfi G, Gervasoni N, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. *Biol Psychiatry* 2005;57(9):1068–1072.10.1016/j.biopsych.2005.01.008 [PubMed: 15860348]
12. Russo-Neustadt AA, Alejandre H, Garcia C, et al. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. *Neuropsychopharmacology* 2004;29(12):2189–2199.10.1038/sj.npp.1300514 [PubMed: 15199375]
13. Altar CA, Whitehead RE, Chen R, et al. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. *Biol Psychiatry* 2003;54(7):703–709.10.1016/S0006-3223(03)00073-8 [PubMed: 14512210]
14. Dias BG, Banerjee SB, Duman RS, et al. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. *Neuropharmacology* 2003;45(4):553–563.10.1016/S0028-3908(03)00198-9 [PubMed: 12907316]
15. Hellweg R, Ziegenhorn A, Heuser I, et al. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. *Pharmacopsychiatry* 2008;41(2):66–71.10.1055/s-2007-1004594 [PubMed: 18311687]
16. Jacobsen JP, Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. *Brain Res* 2004;1024(1–2):183–192.10.1016/j.brainres.2004.07.065 [PubMed: 15451381]
17. Groves JO. Is it time to reassess the BDNF hypothesis of depression? *Mol Psychiatry* 2007;12(12):1079–1088.10.1038/sj.mp.4002075 [PubMed: 17700574]
18. Pan W, Banks WA, Fasold MB, et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. *Neuropharmacology* 1998;37(12):1553–1561.10.1016/S0028-3908(98)00141-5 [PubMed: 9886678]
19. Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. *Neurobiol Aging* 2005;26(1):115–123.10.1016/j.neurobiolaging.2004.03.002 [PubMed: 15585351]
20. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. *J Clin Psychiatry* 2008;69:946–958.10.4088/JCP.v69n0610 [PubMed: 18435563]
21. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 2000;47(4):351–354.10.1016/S0006-3223(99)00230-9 [PubMed: 10686270]
22. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry* 2006;63(8):856–864.10.1001/archpsyc.63.8.856 [PubMed: 16894061]
23. Garcia LS, Comim CM, Valvassori SS, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32(1):140–144.10.1016/j.pnpbp.2007.07.027 [PubMed: 17884272]

24. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3- hydroxy-5-methylisoxazole-4-propionic acid receptors. *Biol Psychiatry* 2008;63(4):349–352.10.1016/j.biopsych.2007.05.028 [PubMed: 17643398]
25. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. *Nat Neurosci* 2007;10(9):1089–1093.10.1038/nn1971 [PubMed: 17726474]
26. First, MB.; Spitzer, RL.; Williams, AL., et al. *Structured Clinical Interview for DSM-IV (SCID)*. Washington, DC: American Psychiatric Association; 1995.
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979;134:382–389.10.1192/bjp.134.4.382 [PubMed: 444788]
28. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;23:56–62.10.1136/jnnp.23.1.56 [PubMed: 14399272]
29. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. *Mod Probl Pharmacopsychiatry* 1974;7(0):151–169. [PubMed: 4412100]
30. Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. *J Oper Psychiatr* 1980;11:48–65.
31. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychol Rep* 1962;10:799–812.
32. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry* 1978;133:429–435.10.1192/bjp.133.5.429 [PubMed: 728692]
33. Poduslo JF, Curran GL. Permeability at the blood-brain and blood- nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. *Brain Res Mol Brain Res* 1996;36(2):280–286.10.1016/0169-328X(95)00250-V [PubMed: 8965648]
34. Marano CM, Phatak P, Vemulapalli UR, et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. *J Clin Psychiatry* 2007;68(4):512–517. [PubMed: 17474805]
35. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. *Neuropsychopharmacology* 2007;32(4):793–802.10.1038/sj.npp.1301178 [PubMed: 16936714]




Figure 1.
BDNF Values and MADRS Scores Over 230 Minutes in Subjects With Major Depressive Disorder (treatment resistant) who Did and Did Not Respond to ketamine (N=23)
* $p < .05$, *** $p < .001$ after Bonferroni correction.
Abbreviations: BDNF = brain derived neurotrophic factor, MADRS = Montgomery-Asberg Depression Rating Scale.

Table 1

Demographic and Clinical Characteristics of Subjects With Major Depressive Disorder (treatment resistant) Receiving Ketamine (N = 23)

Characteristic	Mean	SD
Age, y	43.9	13.9
Age at onset, y	19.2	8.5
Body mass index	30.9	7.6
Illness duration, y	24.8	12.4
Episode duration, mo	80.7	108.5
No. of episodes	31.7	45.3
MADRS score	33.5	4.3
HDRS-17 score	20.8	4.4
BDI score	26.0	7.3
BPRS score	36.9	5.7
YMRS score	5.0	3.1
	N	%
Sex, male	14	61
Education, college	12	63 ^a

^aInformation was unavailable for a few subjects.

Abbreviations: BDI = Beck Depression Inventory, BPRS = Brief Psychiatric Rating Scale, HDRS-17 = 17-item Hamilton Depression Rating Scale, MADRS = Montgomery-Asberg Depression Rating Scale, YMRS = Young Mania Rating Scale.